Iodine-125 Seed Brachytherapy In Patients With Unresectable Or Local-Regional Recurrent Intrahepatic Cholangiocarcinoma

Purpose:The aim of this article is to evaluate the feasibility and safety of Iodine-125seed(¹²⁵I)brachytherapy for patients with unresectable or recurrent intrahepatic cholangiocarcinoma（i CCA）.Materials and Methods:Between December 2013 and October 2020,we retrospectively analyzed data from 43 patients with unresectable or local-regional recurrent i CCA.Local progression-free survival（LTPFS）and local disease control rate（LDCR）were evaluated as primary endpoints.The second endpoint were overall survival（OS）and major complication rate after ¹²⁵I brachytherapy.Results:Between December 2013 and October 2020,43 patients with 56 tumors met selection criteria and were included in this study.After a median follow-up of 12 months（range 4-12months）,the LDCR at 1-,3-,6-,and 12 months were 100%,72.5%,48.8%,and 16.3%,respectively.The median LTPFS was 4.6 months（95%CI2.3-7.0months）.The 3,6,and 12 OS rates were 100%,100%,93.0%and 53.5%,respectively.No treatment-related mortality occurred,and complications were minimal.Conclusions:For patients with unresectable or local-regional recurrent intrahepatic cholangiocarcinoma,¹²⁵I brachytherapy is a safe and effective alternative treatment and can provide long-term local control and increased survival.